Document Detail


Intravenous epoprostenol versus high dose inhaled iloprost for long-term treatment of pulmonary hypertension.
MedLine Citation:
PMID:  20601049     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Intravenous prostacyclin (iv PGI) and inhaled Iloprost (inh ilo) are established therapies in pulmonary arterial hypertension (PAH), however comparative data are lacking.
METHODS AND PATIENTS: We performed a long-term open label comparison trial of iv PGI or high dose inh ilo in 24 patients with severe PAH: 12 patients (9 female, 40 +/- 14 years, 10 idiopathic PAH, 2 PAH in connective tissue disease CTD) received iv PGI, whereas 12 patients (7 female, 43 +/- 12 years, 5 IPAH, 6 CTD, 1 porto-pulmonary hypertension) were commenced on inh ilo with a median dose of 120 μg/24 h. Haemodynamic parameters and 6 min walking distance (6MWD) at baseline did not differ between both groups.
RESULTS: After 3 months therapy, patients on iv PGI showed a significant increase in 6MWD from 220 to 280 m (p < 0.01), whereas patients on high dose inh ilo increased 6MWD from 200 to 275 m (p < 0.05). The event free follow up was 23 [1-76] months in the iv PGI2I group, and 16 [7-38] months in the high dose inh ilo group (p < 0.05). Patients with a 6MWD ≥ 300 m after 3 months therapy had a significantly longer event free follow up [16 vs. 35 months; p < 0.004].
CONCLUSION: In this patient population with severe pulmonary hypertension of different etiologies, event free follow up on treatment with iv PGI is significantly longer compared to high dose inh ilo. The 6MWD after 3 months treatment might be predictive for long term outcome.
Authors:
Frank Reichenberger; Ann Mainwood; Nicholas W Morrell; Jayan Parameshwar; Joanna Pepke-Zaba
Related Documents :
19463019 - Management of hypertension with the fixed combination of perindopril and amlodipine in ...
3905219 - Serum beta 2-microglobulin in systemic sclerosis.
17885779 - Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy seco...
12860219 - Efficacy and safety of berberine for congestive heart failure secondary to ischemic or ...
2893529 - International beta-blocker review in acute and postmyocardial infarction.
14564329 - Metoprolol cr/xl in postmyocardial infarction patients with chronic heart failure: expe...
18412239 - Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: propen...
20142519 - Clinical effect of neutralizing antibodies to interferon beta that persist long after c...
20410619 - Metabolic syndrome as a risk factor for postoperative kidney injury after off-pump coro...
Publication Detail:
Type:  Journal Article     Date:  2010-06-25
Journal Detail:
Title:  Pulmonary pharmacology & therapeutics     Volume:  24     ISSN:  1522-9629     ISO Abbreviation:  Pulm Pharmacol Ther     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9715279     Medline TA:  Pulm Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  169-73     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Pulmonary Vascular Diseases Unit Papworth Hospital, Cambridge, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and characterization of ?-adrenergic receptors in isolated primary equine tracheal ep...
Next Document:  Biomarkers in asthma and allergic rhinitis.